Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.
Gomez-Bougie P et al. Cancer Biol Ther. 2014 Dec 17:0. [Epub ahead of print].
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS et al. Haematologica. 2014 Dec 15. pii: haematol.2014.117531. [Epub ahead of print].
Doxorubicin Overcomes Resistance to Drozitumab by Antagonizing Inhibitor of Apoptosis Proteins (IAPs).
Zinonos I et al. Anticancer Res. 2014 Dec;34(12):7007-20.
Investigation of the Enantiomerization Barriers of the Phthalimidone Derivatives EM12 and Lenalidomide by Dynamic Electrokinetic Chromatography.
Walz S et al. Electrophoresis. 2014 Dec 11. doi: 10.1002/elps.201400499. [Epub ahead of print].
Quantitative Superresolution Microscopy Reveals Differences in Nuclear DNA Organization of Multiple Myelomaand Monoclonal Gammopathy of Undetermined Significance.
Sathitruangsak C et al. J Cell Biochem. 2014 Dec 10. doi: 10.1002/jcb.25030. [Epub ahead of print].
Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma.
Krzeminski P et al. Biochim Biophys Acta. 2014 Dec 10. pii: S1874-9399(14)00296-X. doi: 10.1016/j.bbagrm.2014.12.002. [Epub ahead of print].
p53 suppresses CCL2-induced subcutaneous tumor xenograft.
Tang X et al. Tumour Biol. 2014 Dec 11. [Epub ahead of print].
IL-17/miR-192/IL-17Rs Regulatory Feedback Loop Facilitates Multiple Myeloma Progression.
Sun Y et al. PLoS One. 2014 Dec 9;9(12):e114647. doi: 10.1371/journal.pone.0114647. eCollection 2014.
Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.
Luo Y et al. Tumour Biol. 2014 Dec 7. [Epub ahead of print].
Novel Lys63-Linked Ubiquitination of IKKβ Induces STAT3 Signaling.
Gallo LH et al. Cell Cycle. 2014 Dec 8:0. [Epub ahead of print].
ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.
Dhyani A et al. Eur J Cancer. 2014 Dec 4. pii: S0959-8049(14)01136-8. doi: 10.1016/j.ejca.2014.11.012. [Epub ahead of print].
Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells.
Ghurye RR et al. Cytokine. 2014 Dec 4. pii: S1043-4666(14)00596-1. doi: 10.1016/j.cyto.2014.11.013. [Epub ahead of print].
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
Weinhold N et al. Haematologica. 2014 Dec 5. pii: haematol.2014.118786. [Epub ahead of print].
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.
Muz B et al. Blood Cancer J. 2014 Dec 5;4:e262. doi: 10.1038/bcj.2014.82.
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Clemens J et al. Cancer Chemother Pharmacol. 2014 Dec 5. [Epub ahead of print].
Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes.
Cornish Carmony K et al. Chembiochem. 2014 Dec 4. doi: 10.1002/cbic.201402491. [Epub ahead of print].
Ectopic MicroRNA-150-5p Transcription Sensitizes Glucocorticoid Therapy Response in MM1S Multiple MyelomaCells but Fails to Overcome Hormone Therapy Resistance in MM1R Cells.
Palagani A et al. PLoS One. 2014 Dec 4;9(12):e113842. doi: 10.1371/journal.pone.0113842. eCollection 2014.
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J et al. Oncotarget. 2014 Dec 2. [Epub ahead of print].
Role of osteocytes in multiple myeloma bone disease.
Delgado-Calle J et al. Curr Opin Support Palliat Care. 2014 Dec;8(4):407-13. doi: 10.1097/SPC.0000000000000090.
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
Leotta M et al. J Cell Physiol. 2014 Dec;229(12):2106-16. doi: 10.1002/jcp.24669